Literature DB >> 8750922

Effects of mibefradil on intracellular Ca2+ release in cultured rat cardiac fibroblasts and human platelets.

M Eberhard1, K Miyagawa, K Hermsmeyer, P Erne.   

Abstract

The Ca2+ antagonist mibefradil at supratherapeutic concentrations induced a sustained increase of cytosolic Ca2+ in cultured rat cardiac fibroblasts and human platelets which lack sensitivity to K+ depolarization and Ca2+ channel block by verapamil or other Ca2+ antagonists. At concentrations above 10 microM, mibefradil elevated substantially cytosolic [Ca2+] without affecting the peak level of agonist-induced Ca2+ transients. These Ca2+-mobilizing actions of 10 or 100 microM mibefradil stand in contrast to the Ca2+ antagonism and relaxation of vascular muscle at 1 microM concentrations. Since a substantial part of mibefradil-induced increase in cytosolic Ca2+ was independent of extracellular Ca2+, and in order to define better the mechanism of Ca2+ increase, we exposed permeabilized cultured rat cardiac fibroblasts and human platelets to mibefradil at concentrations sufficiently high to identify covert effects. In permeabilized fibroblasts or platelets mibefradil at concentrations above 10 microM activated dose-dependent Ca2+ release from intracellular Ca2+ stores. Verapamil had no effect at concentrations of up to 100 microM. Mibefradil-induced Ca2+ release was not affected by ryanodine, thapsigargin, removal of ATP or dithioerythreitol, indicating that neither Ca2+ - nor disulfide reagent-induced Ca2+ release were involved and that mibefradil did not release Ca2+ by inhibition of the Ca2+-ATPase pump of endoplasmic reticulum. The rate, but not the amplitude, of mibefradil-induced Ca2+ release is increased up to fourfold in the presence of pentosan polysulphate or heparin, two potent inhibitors of inositol 1,4,5-trisphosphate-induced Ca2+ release. Depletion of Ca2+ stores of permeabilized cells inositol 1,4,5-trisphosphate in the presence of thapsigargin completely blocked mibefradil-induced Ca2+ release, and depletion of Ca2+ stores by mibefradil prevented further Ca2+ release by inositol 1,4,5-trisphosphate. Mibefradil at supratherapeutic concentrations (> or = microM) thus mobilized Ca2+ from an inositol 1,4,5-trisphosphate-sensitive Ca2+ pool in cultured rat cardiac fibroblasts and human platelets.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8750922     DOI: 10.1007/bf00168921

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  30 in total

1.  Metabolism of calcium antagonist Ro 40-5967: a case history of the use of diode-array u.v. spectroscopy and thermospray-mass spectrometry in the elucidation of a complex metabolic pathway.

Authors:  H R Wiltshire; S R Harris; K J Prior; U M Kozlowski; E Worth
Journal:  Xenobiotica       Date:  1992-07       Impact factor: 1.908

2.  A set of programs for analysis of kinetic and equilibrium data.

Authors:  M Eberhard
Journal:  Comput Appl Biosci       Date:  1990-07

3.  Lack of negative inotropic effects of the new calcium antagonist Ro 40-5967 in patients with stable angina pectoris.

Authors:  M C Portegies; R Schmitt; C J Kraaij; S H Braat; A Gassner; F Hagemeijer; H Pozenel; G Prager; J W Viersma; E E van der Wall
Journal:  J Cardiovasc Pharmacol       Date:  1991-11       Impact factor: 3.105

Review 4.  Calcium-channel drugs: structure-function relationships and selectivity of action.

Authors:  D J Triggle
Journal:  J Cardiovasc Pharmacol       Date:  1991       Impact factor: 3.105

5.  In vitro pharmacologic profile of Ro 40-5967, a novel Ca2+ channel blocker with potent vasodilator but weak inotropic action.

Authors:  W Osterrieder; M Holck
Journal:  J Cardiovasc Pharmacol       Date:  1989-05       Impact factor: 3.105

Review 6.  Pharmacokinetics of calcium antagonists.

Authors:  J L Reid; P A Meredith; R Donnelly; H L Elliott
Journal:  J Cardiovasc Pharmacol       Date:  1988       Impact factor: 3.105

7.  Measurement of receptor induced changes in intracellular free calcium in human platelets.

Authors:  P Erne; E Mittelholzer; E Bürgisser; R Flückiger; F R Bühler
Journal:  J Recept Res       Date:  1984

8.  Calcium and magnesium binding to rat parvalbumin.

Authors:  M Eberhard; P Erne
Journal:  Eur J Biochem       Date:  1994-05-15

Review 9.  Position of calcium antagonists in antihypertensive therapy.

Authors:  F R Bühler; P Bolli; P Erne; W Kiowski; F B Müller; U L Hulthén; B H Ji
Journal:  J Cardiovasc Pharmacol       Date:  1985       Impact factor: 3.105

10.  The structurally novel Ca2+ channel blocker Ro 40-5967, which binds to the [3H] desmethoxyverapamil receptor, is devoid of the negative inotropic effects of verapamil in normal and failing rat hearts.

Authors:  J P Clozel; M Véniant; W Osterrieder
Journal:  Cardiovasc Drugs Ther       Date:  1990-06       Impact factor: 3.727

View more
  4 in total

1.  Induction of apoptosis by the calcium antagonist mibefradil correlates with depolarization of the membrane potential and decreased integrin expression in human lens epithelial cells.

Authors:  Barbara Nebe; Friederike Kunz; Annelie Peters; Joachim Rychly; Thomas Noack; Ria Beck
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-04-07       Impact factor: 3.117

2.  T-type calcium channel antagonists, mibefradil and NNC-55-0396 inhibit cell proliferation and induce cell apoptosis in leukemia cell lines.

Authors:  Weifeng Huang; Chunjing Lu; Yong Wu; Shou Ouyang; Yuanzhong Chen
Journal:  J Exp Clin Cancer Res       Date:  2015-05-21

3.  Mibefradil alters intracellular calcium concentration by activation of phospholipase C and IP3 receptor function.

Authors:  Guilherme H Souza Bomfim; Erna Mitaishvili; Talita Ferreira Aguiar; Rodrigo S Lacruz
Journal:  Mol Biomed       Date:  2021-04-30

4.  Prevention of lens epithelial cell growth in vitro using mibefradil-containing PLGA micro particles.

Authors:  Arne Weidmann; Sabine Kwittner; Ria Beck; Joachim Teller; Ludwig Jonas; J Barbara Nebe
Journal:  Open Ophthalmol J       Date:  2008-06-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.